|
1
|
World Health Organization. WHO
Director-General's remarks at the media briefing on 2019-nCoV on 11
February 2020. Available from: urihttps://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020simplehttps://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
|
|
2
|
Lu H, Stratton CW and Tang YW: Outbreak of
pneumonia of unknown etiology in Wuhan, China: The mystery and the
miracle. J Med Virol. 92:401–402. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
World Health Organization. WHO
Director-General's opening remarks at the media briefing on
COVID-19-11 March 2020. Available from: urihttps://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020simplehttps://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020.
|
|
4
|
World Health Organization. WHO
Director-General's opening remarks at the media briefing on
COVID-19-11 October 2020. Available from: urihttps://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf?sfvrsn=49dc56e1_4&download=truesimplehttps://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf?sfvrsn=49dc56e1_4&download=true.
|
|
5
|
Chan JF, Yuan S, Kok KH, To KK, Chu H,
Yang J, Xing F, Liu J, Yip CC, Poon RW, et al: A familial cluster
of pneumonia associated with the 2019 novel coronavirus indicating
person-to-person transmission: A study of a family cluster. Lancet.
395:514–523. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong
Y, Ren R, Leung KSM, Lau EHY, Wong JY, et al: Early transmission
dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.
N Engl J Med. 382:1199–1207. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Farsalinos K, Niaura R, Le Houezec J,
Barbouni A, Tsatsakis A, Kouretas D, Vantarakis A and Poulas K:
Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of
the nicotinic cholinergic system. Toxicol Rep. 7:658–663.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu
Y, Zhang L, Fan G, Xu J, Gu X, et al: Clinical features of patients
infected with 2019 novel coronavirusin Wuhan, China. Lancet.
395:497–506. 2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ioannidis JPA, Axfors C and
Contopoulos-Ioannidis DG: Population-level COVID-19 mortality risk
for non-elderly individuals overall and for non-elderly individuals
without underlying diseases in pandemic epicenters. Environ Res.
188(109890)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Nasi A, McArdle S, Gaudernack G, Westman
G, Melief C, Rockberg J, Arens R, Kouretas D, Sjölin J and Mangsbo
S: Reactive oxygen species as an initiator of toxic innate immune
responses in retort to SARS-CoV-2 in an ageing population, consider
N-acetylcysteine as early therapeutic intervention. Toxicol Rep.
7:768–771. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from
patients with pneumonia in China, 2019. N Engl J Med. 382:727–733.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Amini Pouya M, Afshani SM, Maghsoudi AS,
Hassani S and Mirnia K: Classification of the present
pharmaceutical agents based on the possible effective mechanism on
the COVID-19 infection. Daru: Jul 30, 2020 (Epub ahead of print).
doi: 10.1007/s40199-020-00359-4.
|
|
13
|
Park WB, Kwon NJ, Choi SJ, Kang CK, Choe
PG, Kim JY, Yun J, Lee GW, Seong MW, Kim NJ, et al: Virus isolation
from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci.
35(e84)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tian X, Li C, Huang A, Xia S, Lu S, Shi Z,
Lu L, Jiang S, Yang Z, Wu Y and Ying T: Potent binding of 2019
novel coronavirus spike protein by a SARS coronavirus-specific
human monoclonal antibody. Emerg Microbes Infect. 9:382–385.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo
IM, Halepoto DM, Iqbal M, Usmani AM, Hajjar W and Ahmed N: Novel
coronavirus 2019-nCoV: Prevalence, biological and clinical
characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med
Pharmacol Sci. 24:2012–2019. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ji W, Wang W, Zhao X, Zai J and Li X:
Cross-species transmission of the newly identified coronavirus
2019-nCoV. J Med Virol. 92:433–440. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang J, Liang J, Cheng J, Guo Y and Zeng
L: Deep learning based image reconstruction algorithm for
limited-angle translational computed tomography. PLoS One.
15(e0226963)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sundararaman A, Ray M, Ravindra PV and
Halami PM: Role of probiotics to combat viral infections with
emphasis on COVID-19. Appl Microbiol Biotechnol. 104:8089–8104.
2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang C, Hornby PW, Hayden FG and Gao GF: A
novel coronavirus outbreak of global health concern. Lancet.
395:470–473. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Business Daily: China locks down two
cities to curb virus outbreak. Available from: urihttps://www.businessdailyafrica.com/news/world/China-locks-down-two-cities-to-curb-virus-outbreak/4259366-5428676-xkv9uo/index.htmlsimplehttps://www.businessdailyafrica.com/news/world/China-locks-down-two-cities-to-curb-virus-outbreak/4259366-5428676-xkv9uo/index.html.
|
|
22
|
Goumenou M, Sarigiannis D, Tsatsakis A,
Anesti O, Docea AO, Petrakis D, Tsoukalas D, Kostoff R, Rakitskii
V, Spandidos DA, et al: COVID-19 in Northern Italy: An integrative
overview of factors possibly influencing the sharp increase of the
outbreak (Review). Mol Med Rep. 22:20–32. 2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Torequl Islam M, Nasiruddin M, Khan IN,
Mishra SK, Kudrat-E-Zahan M, Alam Riaz T, Ali ES, Rahman MS,
Mubarak MS, Martorell M, et al: A perspective on emerging
therapeutic interventions for COVID-19. Front Public Health.
8(281)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tsatsakis A, Petrakis D, Nikolouzakis TK,
Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis
C, Aschner M and Hernández AF: COVID-19, an opportunity to
reevaluate the correlation between long-term effects of
anthropogenic pollutants on viral epidemic/pandemic events and
prevalence. Food Chem Toxicol. 141(111418)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Del Rio C and Malani PN: COVID-19-New
insights on a rapidly changing epidemic. JAMA. 323:1339–1340.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lukassen S, Chua RL, Trefzer T, Kahn NC,
Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW, et
al: SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in
bronchial transient secretory cells. EMBO J.
39(e105114)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Izaguirre G: The proteolytic regulation of
virus cell entry by furin and other proprotein convertases.
Viruses. 11(837)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Kirchdoerfer RN, Cottrell CA, Wang N,
Pallesen J, Yassine HM, Turner HL, Corbett KS, Graham BS, McLellan
JS and Ward AB: Pre-fusion structure of a human coronavirus spike
protein. Nature. 531:118–121. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Li F: Structure, function, and evolution
of coronavirus spike proteins. Annu Rev Virol. 3:237–261.
2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Walls AC, Tortorici MA, Snijder J, Xiong
X, Bosch BJ, Rey FA and Veesler D: Tectonic conformational changes
of a coronavirus spike glycoprotein promote membrane fusion. Proc
Natl Acad Sci USA. 114:11157–11162. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Park JE, Li K, Barlan A, Fehr AR, Perlman
S, McCray PB Jr and Gallagher T: Proteolytic processing of Middle
East respiratory syndrome coronavirus spikes expands virus tropism.
Proc Natl Acad Sci USA. 113:12262–12267. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hoffmann M, Kleine-Weber H, Schroeder S,
Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH,
Nitsche A, et al: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2
and is blocked by a clinically proven protease inhibitor. Cell.
181:271–280.e8. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kawase M, Kataoka M, Shirato K and
Matsuyama S: Biochemical analysis of coronavirus spike glycoprotein
conformational intermediates during membrane fusion. J Virol.
93:e00785–19. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Walls AC, Park YJ, Tortorici MA, Wall A,
McGuire AT and Veesler D: Structure, function, and antigenicity of
the SARS-CoV-2 spike glycoprotein. Cell. 181:281–292.e6.
2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Heurich A, Hofmann-Winkler H, Gierer S,
Liepold T, Jahn O and Pohlmann S: TMPRSS2 and ADAM17 cleave ACE2
differentially and only proteolysis by TMPRSS2 augments entry
driven by the severe acute respiratory syndrome coronavirus spike
protein. J Virol. 88:1293–1307. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wrapp D, Wang N, Corbett KS, Goldsmith JA,
Hsieh CL, Abiona O, Graham BS and McLellan JS: Cryo-EM structure of
the 2019-nCoV spike in the prefusion conformation. Science.
367:1260–1263. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y and
Zuo W: Single-Cell RNA expression profiling of ACE2, the receptor
of SARS-CoV-2. Am J Respir Crit Care Med. 202:756–759.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Wang PH and Chen Y: Increasing host
cellular receptor-angiotensin-converting enzyme 2(ACE2) expression
by coronavirus may facilitate 2019-nCoV infection. bioRxiv: Feb 27,
2020 (Epub ahead of print). doi: urihttps://doi.org/10.1101/2020.02.24.963348simplehttps://doi.org/10.1101/2020.02.24.963348.
|
|
39
|
Zhang H, Kang Z, Gong H, Xu D, Wang J, Li
Z, Cui X, Xiao J, Meng T, Zhou W, et al: The digestive system is a
potential route of 2019-nCov infection: A bioinformatics analysis
based on single-cell transcriptomes. bioRxiv: Jan 31, 2020 (Epub
ahead of print). doi: urihttps://doi.org/10.1101/2020.01.30.927806simplehttps://doi.org/10.1101/2020.01.30.927806.
|
|
40
|
Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu
GM and Zhang LJ: Coronavirus disease 2019 (COVID-19): A perspective
from China. Radiology. 296:E15–E25. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zhang G, Zhang J, Wang B, Zhu X, Wang Q
and Qiu S: Analysis of clinical characteristics and laboratory
findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: A retrospective analysis. Respir Res. 21(74)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Tang A, Tong ZD, Wang HL, Dai YX, Li KF,
Liu JN, Wu WJ, Yuan C, Yu ML, Li P and Yan JB: Detection of novel
coronavirus by RT-PCR in stool specimen from asymptomatic child,
China. Emerg Infect Dis. 26:1337–1339. 2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Corman VM, Landt O, Kaiser M, Molenkamp R,
Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J, Schmidt ML,
et al: Detection of 2019 novel coronavirus (2019-nCoV) by real-time
RT-PCR. Euro Surveill. 25(2000045)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chu DK, Pan Y, Cheng SM, Hui KP, Krishnan
P, Liu Y, Ng DY, Wan CKC, Yang P, Wang Q, et al: Molecular
diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of
pneumonia. Clin Chem. 66:549–555. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Xiao SY, Wu Y and Liu H: Evolving status
of the 2019 novel coronavirus infection: Proposal of conventional
serologic assays for disease diagnosis and infection monitoring. J
Med Virol. 92:464–467. 2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Tahmasebi S, Khosh E and Esmaeilzadeh A:
The outlook for diagnostic purposes of the 2019-novel coronavirus
disease. J Cell Physiol. 235:9211–9229. 2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Liu R, Liu X, Yuan L, Han H, Shereen MA,
Zhen J, Niu Z, Li D, Liu F, Wu K, et al: Analysis of adjunctive
serological detection to nucleic acid test for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
diagnosis. Int Immunopharmacol. 86(106746)2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Perera RA, Mok CK, Tsang OT, Lv H, Ko RL,
Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, et al: Serological
assays for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), March 2020. Euro Surveill. 25(2000421)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Vieira MA, Vieira CP, Borba AS, Melo MC,
Oliveira MS, Melo RM, Nunes VV, Santana WS and Aguiar YA:
Sequential serological surveys in the early stages of the
coronavirus disease epidemic: Limitations and perspectives. Rev Soc
Bras Med Trop. 53(e20200351)2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, Guo
Y, Fang L, Zhang B, Zhang G and Guo X: A method to prevent
SARS-CoV-2 IgM false positives in gold immunochromatography and
enzyme-linked immunosorbent assays. J Clin Microbiol. 58:e00375–20.
2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Thachil A, Gerber PF, Xiao CT, Huang YW
and Opriessnig T: Development and application of an ELISA for the
detection of porcine deltacoronavirus IgG antibodies. PLoS One.
10(e0124363)2015.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Zhao S, Smits C, Schuurman N, Barnum S,
Pusterla N, Kuppeveld FV, Bosch BJ, Maanen KV and Egberink H:
Development and validation of a S1 protein-based ELISA for the
specific detection of antibodies against equine coronavirus.
Viruses. 11(1109)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sunwoo HH, Palaniyappan A, Ganguly A,
Bhatnagar PK, Das D, El-Kadi AO and Suresh MR: Quantitative and
sensitive detection of the SARS-CoV spike protein using bispecific
monoclonal antibody-based enzyme-linked immunoassay. J Virol
Methods. 187:72–78. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
He Y, Lu H, Siddiqui P, Zhou Y and Jiang
S: Receptor-binding domain of severe acute respiratory syndrome
coronavirus spike protein contains multiple conformation-dependent
epitopes that induce highly potent neutralizing antibodies. J
Immunol. 174:4908–4915. 2005.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Lu H: Drug treatment options for the
2019-new coronavirus (2019-nCoV). Biosci Trends. 14:69–71.
2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Chu CM, Cheng VC, Hung IF, Wong MM, Chan
KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, et al: Role of
lopinavir/ritonavir in the treatment of SARS: Initial virological
and clinical findings. Thorax. 59:252–256. 2004.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Chan JF, Yao Y, Yeung ML, Deng W, Bao L,
Jia L, Li F, Xiao C, Gao H, Yu P, et al: Treatment with
Lopinavir/Ritonavir or Interferon-β1b improves outcome of MERS-CoV
infection in a nonhuman primate model of common marmoset. J Infect
Dis. 212:1904–1913. 2015.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo
YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, et al: A Review of
SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci.
21(2657)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Cao B, Zhang D and Wang C: A trial of
lopinavir-ritonavir in covid-19. Reply. N Engl J Med.
382(e68)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Warren TK, Jordan R, Lo MK, Ray AS,
Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, et
al: Therapeutic efficacy of the small molecule GS-5734 against
Ebola virus in rhesus monkeys. Nature. 531:381–385. 2016.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Gordon CJ, Tchesnokov EP, Feng JY, Porter
DP and Gotte M: The antiviral compound remdesivir potently inhibits
RNA-dependent RNA polymerase from Middle East respiratory syndrome
coronavirus. J Biol Chem. 295:4773–4779. 2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sheahan TP, Sims AC, Graham RL, Menachery
VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I,
et al: Broad-spectrum antiviral GS-5734 inhibits both epidemic and
zoonotic coronaviruses. Sci Transl Med. 9(eaal3653)2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Martinez MA: Compounds with therapeutic
potential against novel respiratory 2019 coronavirus. Antimicrob
Agents Chemother. 64:e00399–20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Jean SS, Lee PI and Hsueh PR: Treatment
options for COVID-19: The reality and challenges. J Microbiol
Immunol Infect. 53:436–443. 2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lo MK, Jordan R, Arvey A, Sudhamsu J,
Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D,
Clarke MO, et al: GS-5734 and its parent nucleoside analog inhibit
Filo-, Pneumo-, and Paramyxoviruses. Sci Rep.
7(43395)2017.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mulangu S, Dodd LE, Davey RT Jr, Tshiani
Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D,
Tshomba Oloma A, Ibanda A, et al: A randomized, controlled trial of
ebola virus disease therapeutics. N Engl J Med. 381:2293–2303.
2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Brown AJ, Won JJ, Graham RL, Dinnon KH
III, Sims AC, Feng JY, Cihlar T, Denison MR, Baric RS and Sheahan
TP: Broad spectrum antiviral remdesivir inhibits human endemic and
zoonotic deltacoronaviruses with a highly divergent RNA dependent
RNA polymerase. Antiviral Res. 169(104541)2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu
M, Shi Z, Hu Z, Zhong W and Xiao G: Remdesivir and chloroquine
effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 30:269–271. 2020.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Jordan PC, Stevens SK and Deval J:
Nucleosides for the treatment of respiratory RNA virus infections.
Antivir Chem Chemother. 26(2040206618764483)2018.PubMed/NCBI View Article : Google Scholar
|
|
70
|
de Wit E, Feldmann F, Cronin J, Jordan R,
Okumura A, Thomas T, Scott D, Cihlar T and Feldmann H: Prophylactic
and therapeutic remdesivir (GS-5734) treatment in the rhesus
macaque model of MERS-CoV infection. Proc Natl Acad Sci USA.
117:6771–6776. 2020.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Holshue ML, DeBolt C, Lindquist S, Lofy
KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural
A, et al: First Case of 2019 Novel Coronavirus in the United
States. N Engl J Med. 382:929–936. 2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Available from urihttps://times.hinet.net/mobile/news/22831665simplehttps://times.hinet.net/mobile/news/22831665.
|
|
73
|
Furuta Y, Komeno T and Nakamura T:
Favipiravir (T-705), a broad spectrum inhibitor of viral RNA
polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93:449–463.
2017.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Du YX and Chen XP: Favipiravir:
Pharmacokinetics and concerns about clinical trials for 2019-nCoV
infection. Clin Pharmacol Ther. 108:242–247. 2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Shannon A, Selisko B, Le N, Huchting J,
Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C,
et al: Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the
RNA polymerase. bioRxiv: May 15, 2020 (Epub ahead of print). doi:
10.1101/2020.05.15.098731.
|
|
76
|
Nagata T, Lefor AK, Hasegawa M and Ishii
M: Favipiravir: A new medication for the Ebola virus disease
pandemic. Disaster Med Public Health Prep. 9:79–81. 2015.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Dong L, Hu S and Gao J: Discovering drugs
to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther.
14:58–60. 2020.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Korea Biomedical Review. Physicians work
out treatment guidelines for coronavirus. 2020. Available from:
urihttp://www.koreabiomed.com/news/articleView.html?idxno=7428simplehttp://www.koreabiomed.com/news/articleView.html?idxno=7428.
|
|
79
|
Notice on Adjusting the Usage and Dosage
of Chloroquine Phosphate in Treating COVID-19 Pneumonia. Available
from: urihttp://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtmlsimplehttp://www.nhc.gov.cn/yzygj/s7653p/202002/0293d017621941f6b2a4890035243730.shtml.
|
|
80
|
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,
Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical characteristics
of 138 hospitalized patients with 2019 novel coronavirus-infected
pneumonia in Wuhan, China. JAMA. 323:1061–1069. 2020.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu
P, Liu X, Zhao L, Dong E, Song C, et al: In vitro antiviral
activity and projection of optimized dosing design of
hydroxychloroquine for the treatment of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 71:732–739.
2020.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H,
Li Y, Hu Z, Zhong W and Wang M: Hydroxychloroquine, a less toxic
derivative of chloroquine, is effective in inhibiting SARS-CoV-2
infection in vitro. Cell Discov. 6(16)2020.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Molina JM, Delaugerre C, Le Goff J,
Mela-Lima B, Ponscarme D, Goldwirt L and de Castro N: No evidence
of rapid antiviral clearance or clinical benefit with the
combination of hydroxychloroquine and azithromycin in patients with
severe COVID-19 infection. Med Mal Infect. 50(384)2020.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Gautret P, Lagier JC, Parola P, Hoang VT,
Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE,
et al: Hydroxychloroquine and azithromycin as a treatment of
COVID-19: Results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 56(105949)2020.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Interim clinical guidance for patients
suspected of/confirmed with Covid-19 in Belgium. Availabe from:
urihttps://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf?fbclid=IwAR2PP0GEhBHm2m3zH7c-simplehttps://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf?fbclid=IwAR2PP0GEhBHm2m3zH7c-.
|
|
86
|
Azioni intraprese per favorire la ricerca
e l'accesso ai nuovi farmaci per il trat-tamento del COVID-19.
Availabe from: urihttps://www.aifa.gov.it/-/azioni-intraprese-per-favorire-la-ricerca-e-l-accesso-ai-nuovi-farmaci-per-il-trattamento-del-covid-19simplehttps://www.aifa.gov.it/-/azioni-intraprese-per-favorire-la-ricerca-e-l-accesso-ai-nuovi-farmaci-per-il-trattamento-del-covid-19.
|
|
87
|
Hoffmann M, Mösbauer K, Hofmann-Winkler H,
Kaul A, Kleine-Weber H, Krüger N, Gassen NC, Müller MA, Drosten C
and Pöhlmann S: Chloroquine does not inhibit infection of human
lung cells with SARS-CoV-2. Nature. 585:588–590. 2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Maisonnasse P, Guedj J, Contreras V,
Behillil S, Solas C, Marlin R, Naninck T, Pizzorno A, Lemaitre J,
Gonçalves A, et al: Hydroxychloroquine use against SARS-CoV-2
infection in non-human primates. Nature. 585:584–587.
2020.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Zhang S, Li L, Shen A, Chen Y and Qi Z:
Rational use of tocilizumab in the treatment of novel coronavirus
pneumonia. Clin Drug Investig. 40:511–518. 2020.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Scott LJ: Tocilizumab: A review in
rheumatoid arthritis. Drugs. 77:1865–1879. 2017.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Venkiteshwaran A: Tocilizumab. MAbs.
1:432–438. 2009.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Triestall News. Coronavirus, will
‘To-cilizumab’ be the drug of hope? Available from: urihttps://www.triesteallnews.it/2020/03/14/coronavirus-will-tocilizumab-be-the-drug-of-hope/64simplehttps://www.triesteallnews.it/2020/03/14/coronavirus-will-tocilizumab-be-the-drug-of-hope/64.
|
|
93
|
Costanzo M, De Giglio MAR and Roviello GN:
SARS-CoV-2: Recent reports on antiviral therapies based on
lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine,
remdesivir, favipiravir and other drugs for the treatment of the
new coronavirus. Curr Med Chem. 7:4536–4541. 2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Marinella MA: Routine antiemetic
prophylaxis with dexamethasone during COVID-19: Should oncologists
reconsider? J Oncol Pharm Pract. 26:1482–1485. 2020.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Andreakos E, Papadaki M and Serhan CN:
Dexamethasone, pro-resolving lipid mediators and resolution of
inflammation in COVID-19. Allergy: Sep 21, 2020 (Epub ahead of
print). doi: org/10.1111/all.14595.
|
|
96
|
Ledford H: Coronavirus breakthrough:
Dexamethasone is first drug shown to save lives. Nature.
582(469)2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Shang L, Zhao J, Hu Y, Du R and Cao B: On
the use of corticosteroids for 2019-nCoV pneumonia. Lancet.
395:683–684. 2020.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Mehta P, McAuley DF, Brown M, Sanchez E,
Tattersall RS and Manson JJ: HLH Across Speciality Collaboration,
UK. COVID-19: Consider cytokine storm syndromes and
immunosuppression. Lancet. 395:1033–1034. 2020.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Youssef J, Novosad SA and Winthrop KL:
Infection risk and safety of corticosteroid use. Rheum Dis Clin
North Am. 42:157–176, ix-x. 2016.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Yang Z and Liu J, Zhou Y, Zhao X, Zhao Q
and Liu J: The effect of corticosteroid treatment on patients with
coronavirus infection: A systematic review and meta-analysis. J
Infect. 81:e13–e20. 2020.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Dong L, Xia JW, Gong Y, Chen Z, Yang HH,
Zhang J, He J and Chen XD: Effect of lianhuaqingwen capsules on
airway inflammation in patients with acute exacerbation of chronic
obstructive pulmonary disease. Evid Based Complement Alternat Med.
2014(637969)2014.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang
B, Liu Q, Song Y, Li X, Duan Z, et al: Efficacy and safety of
Lianhuaqingwen capsules, a repurposed Chinese herb, in patients
with coronavirus disease 2019: A multicenter, prospective,
randomized controlled trial. Phytomedicine: May 16, 2020 (Epub
ahead of print) doi: 10.1016/j.phymed.2020.153242.
|
|
103
|
Chen S: Clinical observation of Lianhua
Qingwen capsule combined with ribavirin injection in the treatment
of viral upper respiratory tract infection. Chin Community Doctors.
13(170)2011.
|
|
104
|
Zhao J, Tian SS, Yang J, Liu JF and Zhang
WD: Investigating mechanism of Qing-Fei-Pai-Du-Tang for treatment
of COVID-19 by network pharmacology. Chin Trad Herbal Drugs.
4:829–835. 2020.(In Chinese).
|
|
105
|
Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen
Q, Cheng PL, Yutao W, Zheng J, Yang Z and Zhang F: The Chinese
prescription lianhuaqingwen capsule exerts anti-influenza activity
through the inhibition of viral propagation and impacts immune
function. BMC Complement Altern Med. 17(130)2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Yang Y, Islam MS, Wang J, Li Y and Chen X:
Traditional Chinese medicine in the treatment of patients infected
with 2019-new coronavirus (SARS-CoV-2): A review and perspective.
Int J Biol Sci. 16:1708–1717. 2020.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Xin S, Cheng X, Zhu B, Liao X, Yang F,
Song L, Shi Y, Guan X, Su R, Wang J, et al: Clinical retrospective
study on the efficacy of Qingfei Paidu decoction combined with
Western medicine for COVID-19 treatment. Biomed Pharmacother.
129(110500)2020.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Yende S, Milbrandt EB, Kellum JA, Kong L,
Delude RL, Weissfeld LA and Angus DC: Understanding the potential
role of statins in pneumonia and sepsis. Crit Care Med.
39:1871–1878. 2011.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Chrusciel P, Sahebkar A, Rembek-Wieliczko
M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S,
Blaha MJ, Martin SS, et al: Impact of statin therapy on plasma
adiponectin concentrations: A systematic review and meta-analysis
of 43 randomized controlled trial arms. Atherosclerosis.
253:194–208. 2016.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Reiner Z, Hatamipour M, Banach M, Pirro M,
Al-Rasadi K, Jamialahmadi T, Radenkovic D, Montecucco F and
Sahebkar A: Statins and the COVID-19 main protease: In silico
evidence on direct interaction. Arch Med Sci. 16:490–496.
2020.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao
YC, Yuan Y, Lei F, Chen MM, Yang H, Bai L, et al: In-Hospital use
of statins is associated with a reduced risk of mortality among
individuals with COVID-19. Cell Metab. 32:176–187.e4.
2020.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Pillaiyar T, Manickam M, Namasivayam V,
Hayashi Y and Jung SH: An overview of severe acute respiratory
syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors:
Peptidomimetics and small molecule chemotherapy. J Med Chem.
59:6595–6628. 2016.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Jin Z, Zhao Y, Sun Y, Zhang B, Wang H, Wu
Y, Zhu Y, Zhu C, Hu T, Du X, et al: Structural basis for the
inhibition of SARS-CoV-2 main protease by antineoplastic drug
carmofur. Nat Struct Mol Biol. 27:529–532. 2020.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y,
Zhang B, Li X, Zhang L, Peng C, et al: Structure of M(pro) from
SARS-CoV-2 and discovery of its inhibitors. Nature. 582:289–293.
2020.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Gupta S, Singh AK, Kushwaha PP, Prajapati
KS, Shuaib M, Senapati S and Kumar S: Identification of potential
natural inhibitors of SARS-CoV2 main protease by molecular docking
and simulation studies. J Biomol Struct Dyn: Jun 11, 2020 (Epub
ahead of print). doi: 10.1080/07391102.2020.1776157.
|
|
116
|
Wong SK, Li W, Moore MJ, Choe H and Farzan
M: A 193-amino acid fragment of the SARS coronavirus S protein
efficiently binds angiotensin-converting enzyme 2. J Biol Chem.
279:3197–3201. 2004.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X,
Yu J, Shan S, Zhou B, Song S, et al: Human neutralizing antibodies
elicited by SARS-CoV-2 infection. Nature. 584:115–119.
2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Robbiani DF, Gaebler C, Muecksch F,
Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A,
Finkin S, et al: Convergent antibody responses to SARS-CoV-2 in
convalescent individuals. Nature. 584:437–442. 2020.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Shi R, Shan C, Duan X, Chen Z, Liu P, Song
J, Song T, Bi X, Han C, Wu L, et al: A human neutralizing antibody
targets the receptor binding site of SARS-CoV-2. Nature.
584:120–124. 2020.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Lei C, Qian K, Li T, Zhang S, Fu W, Ding M
and Hu S: Neutralization of SARS-CoV-2 spike pseudotyped virus by
recombinant ACE2-Ig. Nat Commun. 11(2070)2020.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Kong Q, Wu Y, Gu Y, Lv Q, Qi F, Gong S and
Chen X: Analysis of the molecular mechanism of Pudilan (PDL)
treatment for COVID-19 by network pharmacology tools. Biomed
Pharmacother. 128(110316)2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Kumar V, Dhanjal JK, Bhargava P, Kaul A,
Wang J, Zhang H, Kaul SC, Wadhwa R and Sundar D: Withanone and
Withaferin-A are predicted to interact with transmembrane protease
serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J
Biomol Struct Dyn: Jun 16, 2020 (Epub ahead of print). doi:
10.1080/07391102.2020.1775704.
|
|
123
|
Rahman N, Basharat Z, Yousuf M, Castaldo
G, Rastrelli L and Khan H: Virtual screening of natural products
against type ii transmembrane serine protease (TMPRSS2), the
priming agent of coronavirus 2 (SARS-CoV-2). Molecules.
25(2271)2020.PubMed/NCBI View Article : Google Scholar
|
|
124
|
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S,
Li J, Wang H, Yu L, Huang H, et al: Management of corona virus
disease-19 (COVID-19): The Zhejiang experience. Zhejiang Da Xue Xue
Bao Yi Xue Ban. 49:147–157. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
125
|
Morais AHA, Passos TS, Maciel BLL and da
Silva Maia JK: Can probiotics and diet promote beneficial immune
modulation and purine control in coronavirus infection? Nutrients.
12(1737)2020.PubMed/NCBI View Article : Google Scholar
|
|
126
|
Sharifi-Rad J, Rodrigues CF,
Stojanovic-Radic Z, Dimitrijević M, Aleksić A, Neffe-Skocińska K,
Zielińska D, Kołożyn-Krajewska D, Salehi B, Milton Prabu S, et al:
Probiotics: Versatile bioactive components in promoting human
health. Medicina (Kaunas). 56(433)2020.PubMed/NCBI View Article : Google Scholar
|
|
127
|
Infusino F, Marazzato M, Mancone M, Fedele
F, Mastroianni CM, Severino P, Ceccarelli G, Santinelli L,
Cavarretta E, Marullo AGM, et al: Diet supplementation, probiotics,
and nutraceuticals in SARS-CoV-2 infection: A scoping review.
Nutrients. 12(1718)2020.PubMed/NCBI View Article : Google Scholar
|
|
128
|
Wang M, Luo L, Bu H and Xia H: One case of
coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV
with a low CD4+ T-cell count. Int J Infect Dis. 96:148–150.
2020.PubMed/NCBI View Article : Google Scholar
|
|
129
|
Luo Y, Xie Y, Zhang W, Lin Q, Tang G, Wu
S, Huang M, Yin B, Huang J, Wei W, et al: Combination of lymphocyte
number and function in evaluating host immunity. Aging (Albany NY).
11:12685–12707. 2019.PubMed/NCBI View Article : Google Scholar
|
|
130
|
Chen X, Liao B, Cheng L, Peng X, Xu X, Li
Y, Hu T, Li J, Zhou X and Ren B: The microbial coinfection in
COVID-19. Appl Microbiol Biotechnol. 104:7777–7785. 2020.PubMed/NCBI View Article : Google Scholar
|
|
131
|
Zhang G, Hu C, Luo L, Fang F, Chen Y, Li
J, Peng Z and Pan H: Clinical features and short-term outcomes of
221 patients with COVID-19 in Wuhan, China. J Clin Virol.
127(104364)2020.PubMed/NCBI View Article : Google Scholar
|
|
132
|
Wu JH, Li X, Huang B, Su H, Li Y, Luo DJ,
Chen S, Ma L, Wang SH, Nie X and Peng L: Pathological changes of
fatal coronavirus disease 2019 (COVID-19) in the lungs: Report of
10 cases by postmortem needle autopsy. Zhonghua Bing Li Xue Za Zhi.
49:568–575. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
133
|
Wang Z, Hu X, Li Z, Tu C, Wang Y, Pang P,
Zhang H, Zheng X, Liang Y, Shan H and Liu J: Effect of SARS-CoV-2
infection on the microbial composition of upper airway. Infect Drug
Resist. 13:2637–2640. 2020.PubMed/NCBI View Article : Google Scholar
|
|
134
|
Piva S, Filippini M, Turla F, Cattaneo S,
Margola A, De Fulviis S, Nardiello I, Beretta A, Ferrari L, Trotta
R, et al: Clinical presentation and initial management critically
ill patients with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection in Brescia, Italy. J Crit Care. 58:29–33.
2020.PubMed/NCBI View Article : Google Scholar
|
|
135
|
Renteria AE, Endam Mfuna L, Adam D,
Filali-Mouhim A, Maniakas A, Rousseau S, Brochiero E, Gallo S and
Desrosiers M: Azithromycin downregulates gene expression of IL-1β
and pathways involving TMPRSS2 and TMPRSS11D required by
SARS-CoV-2. Am J Respir Cell Mol Biol. 63:707–709. 2020.PubMed/NCBI View Article : Google Scholar
|
|
136
|
Fanin A, Calegari J, Beverina A and
Tiraboschi S: Gruppo di Autoformazione Metodologica (GrAM).
Hydroxychloroquine and azithromycin as a treatment of COVID-19.
Intern Emerg Med. 15:841–843. 2020.PubMed/NCBI View Article : Google Scholar
|
|
137
|
Parra-Lara LG, Martinez-Arboleda JJ and
Rosso F: Azithromycin and SARS-CoV-2 infection: Where we are now
and where we are going. J Glob Antimicrob Resist. 22:680–684.
2020.PubMed/NCBI View Article : Google Scholar
|
|
138
|
Ardal C, Balasegaram M, Laxminarayan R,
McAdams D, Outterson K, Rex JH and Sumpradit N: Antibiotic
development-economic, regulatory and societal challenges. Nat Rev
Microbiol. 18:267–274. 2020.PubMed/NCBI View Article : Google Scholar
|
|
139
|
World Health Organization. Draft landscape
of COVID-19 vaccine candidates. Available from: urihttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinessimplehttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
|
|
140
|
Krammer F: SARS-CoV-2 vaccines in
development. Nature. 586:516–527. 2020.PubMed/NCBI View Article : Google Scholar
|
|
141
|
Bai ZH, Li XR, Wang RB, LIU XR, et al:
Review of industrialized production technology of human inactivated
vaccine based on mammalian cell culture. Chin J Cell Biol.
41:1986–1993. 2019.
|
|
142
|
Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M,
Li Y, Zhu L, Wang N, Lv Z, et al: Development of an inactivated
vaccine candidate for SARS-CoV-2. Science. 369:77–81.
2020.PubMed/NCBI View Article : Google Scholar
|
|
143
|
World's First Phase III clinical trial of
COVID-19 inactivated vaccine begins in UAE. Journal 2020. Available
from: urihttps://www.businesswire.com/news/home/20200717005085/en/simplehttps://www.businesswire.com/news/home/20200717005085/en/.
|
|
144
|
Sinovac. Safety and immunogenicity study
of inactivated vaccine for prophylaxis of SARS-CoV-2 infection
(COVID-19). 2020-04-20. Available from: urihttps://clinicaltrials.gov/ct2/show/NCT04352608?cond=COVID+vaccine&draw=2simplehttps://clinicaltrials.gov/ct2/show/NCT04352608?cond=COVID+vaccine&draw=2.
|
|
145
|
Sinovac. Safety and immunogenicity study
of inactivated vaccine for prophylaxis of SARS-CoV-2 infection
(COVID-19). 2020-05-12. Available from: urihttps://clinicaltrials.gov/ct2/show/NCT04383574simplehttps://clinicaltrials.gov/ct2/show/NCT04383574.
|
|
146
|
Wan Y, Shang J, Sun S, Tai W, Chen J, Geng
Q, He L, Chen Y, Wu J, Shi Z, et al: Molecular mechanism for
antibody-dependent enhancement of coronavirus entry. J Virol.
94:e02015–19. 2020.PubMed/NCBI View Article : Google Scholar
|
|
147
|
Guo ZY, Liu J and Liu X: Progress in
severe acute respiratory syndrome coronavirus 2 vaccine. Chin J
Viral Dis. 10:249–254. 2020.
|
|
148
|
A Study Looking at the Effectiveness and
Safety of a COVID-19 Vaccine in South African Adults. (2020-08-31).
Available from: urihttps://clinicaltrials.gov/ct2/show/NCT04533399?term=vaccine&cond=covid-19&draw=7simplehttps://clinicaltrials.gov/ct2/show/NCT04533399?term=vaccine&cond=covid-19&draw=7.
|
|
149
|
Clover Initiates Phase 1 Clinical Trial
for COVID-19 Vaccine Candidate. (2020-06-19). Available from:
urihttp://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=48&langId=1simplehttp://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=48&langId=1.
|
|
150
|
Geall AJ, Mandl CW and Ulmer JB: RNA: The
new revolution in nucleic acid vaccines. Semin Immunol. 25:152–159.
2013.PubMed/NCBI View Article : Google Scholar
|
|
151
|
Ferraro B, Morrow MP, Hutnick NA, Shin TH,
Lucke CE and Weiner DB: Clinical applications of DNA vaccines:
Current progress. Clin Infect Dis. 53:296–302. 2011.PubMed/NCBI View Article : Google Scholar
|
|
152
|
Mclvor RS: Therapeutic delivery of mRNA:
The medium is the message. Mol Ther. 19:822–823. 2011.PubMed/NCBI View Article : Google Scholar
|
|
153
|
Moderna Announces Phase 3 COVE Study of
mRNA Vaccine Against COVID-19 (mRNA-1273) Begins. (2020-07-27).
Available from: urihttps://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covidsimplehttps://investors.modernatx.com/news-releases/news-release-details/moderna-announces-phase-3-cove-study-mrna-vaccine-against-covid.
|
|
154
|
Study to Describe the Safety, Tolerability
Immunogenicity, Efficacy of RNA Vaccine Candidates Against COVID-19
in Healthy Adults. (2020-09-29). Available from: urihttps://clinicaltrials.gov/ct2/show/NCT04368728simplehttps://clinicaltrials.gov/ct2/show/NCT04368728.
|
|
155
|
COVID-19 vaccine developed by military
medical academy approved for clinical trials. Available from:
urihttp://www.chinadaily.com.cn/a/202003/17/WS5e70b732a31012821727fd62.htmsimplehttp://www.chinadaily.com.cn/a/202003/17/WS5e70b732a31012821727fd62.htm.
|
|
156
|
Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ,
Li JX, Wu SP, Wang BS, Wang Z, Wang L, et al: Safety, tolerability,
and immunogenicity of a recombinant adenovirus type-5 vectored
COVID-19 vaccine: A dose-escalation, open-label, non-randomised,
first-in-human trial. Lancet. 395:1845–1854. 2020.PubMed/NCBI View Article : Google Scholar
|
|
157
|
Li X, Giorgi EE, Marichannegowda MH, Foley
B, Xiao C, Kong XP, Chen Y, Gnanakaran S, Korber B and Gao F:
Emergence of SARS-CoV-2 through recombination and strong purifying
selection. Sci Adv. 6(eabb9153)2020.PubMed/NCBI View Article : Google Scholar
|
|
158
|
Han G and Zhou YH: Possibly critical role
of wearing masks in general population in controlling COVID-19. J
Med Virol: Apr 15, 2020 (Epub ahead of print). doi:
10.1002/jmv.25886.
|
|
159
|
Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R,
Yatoo MI, Patel SK, Pathak M, Malik YS, Dhama K, Singh KP, et al:
SARS-CoV-2/COVID-19 and advances in developing potential
therapeutics and vaccines to counter this emerging pandemic. Ann
Clin Microbiol Antimicrob. 19(40)2020.PubMed/NCBI View Article : Google Scholar
|
|
160
|
Calina D, Hartung T, Docea AO, Spandidos
DA, Egorov AM, Shtilman MI, Carvalho F and Tsatsakis A: COVID-19
vaccines: Ethical framework concerning human challenge studies.
Daru: Aug 27, 2020 (Epub ahead of print). doi:
10.1007/s40199-020-00371-8.
|
